Literature DB >> 24629564

Gypenosides might have neuroprotective and immunomodulatory effects on optic neuritis.

Kaijun Li1, Yi Du2, Qian Fan3, Cheng-Ye Tang1, Jian-Feng He4.   

Abstract

Optic neuritis is a common disease in young adults, inducing apoptosis of retinal ganglion cells, which leads to varying degree of visual function damages, even blindness. As the standard treatment, methylprednisolone pulse therapy can only promote the recovery of visual acuity but not prevent retinal ganglion cell degeneration. It cannot help improve the ultimate visual outcome. Both inflammatory response and endogenous oxidative stress play crucial roles in the progression of optic neuritis. The combination of immunomodulatory and antioxidant is expected to improve the prognosis of the disease by preventing the apoptosis of retinal ganglion cells. Triterpenoids (oleanolic acid derived) were reported to have the dual capacity of simultaneously repressing production of pro-inflammatory mediators and exerting neuroprotective effects through induction of anti-oxidant genes in experimental optic neuritis. Gypenosides with an aglycone mainly of dammarane-type tetracyclic triterpenoids, also has the dual capacity of immune regulation and antioxidation. Both gypenosides and oleanolic acid were reported to have similar roles in hepatoprotection. Beside, gypenosides were reported to have the capacity of modulating the activation of immune cells and the expression of cytokines. In addition, gypenosides showed neuroprotective effect against oxidative injury in dopaminergic neurons and mouse model of Parkinson's disease. Accordingly, we propose that gypenosides have potential neuroprotective and immunomodulatory effects on optic neuritis through antioxidation and immune regulation. The application of gypenosides might prevent the apoptosis of retinal ganglion cells and improve the ultimate visual outcome in patients with optic neuritis.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24629564     DOI: 10.1016/j.mehy.2014.02.030

Source DB:  PubMed          Journal:  Med Hypotheses        ISSN: 0306-9877            Impact factor:   1.538


  6 in total

1.  Gypenoside attenuates renal ischemia/reperfusion injury in mice by inhibition of ERK signaling.

Authors:  Qifa Ye; Y I Zhu; Shaojun Ye; Hong Liu; Xingguo She; Ying Niu; Yingzi Ming
Journal:  Exp Ther Med       Date:  2016-01-29       Impact factor: 2.447

Review 2.  Melatonin as a Therapeutic Resource for Inflammatory Visual Diseases.

Authors:  Marcos L Aranda; María Florencia González Fleitas; Hernán Dieguez; Agustina Iaquinandi; Pablo H Sande; Damián Dorfman; Ruth E Rosenstein
Journal:  Curr Neuropharmacol       Date:  2017       Impact factor: 7.363

3.  Protective Effects of Gynostemma pentaphyllum (var. Ginpent) against Lipopolysaccharide-Induced Inflammation and Motor Alteration in Mice.

Authors:  Andrea Mastinu; Sara Anna Bonini; Marika Premoli; Giuseppina Maccarinelli; Eileen Mac Sweeney; Leilei Zhang; Luigi Lucini; Maurizio Memo
Journal:  Molecules       Date:  2021-01-22       Impact factor: 4.411

Review 4.  Promising Therapeutic Candidate for Myocardial Ischemia/Reperfusion Injury: What Are the Possible Mechanisms and Roles of Phytochemicals?

Authors:  Cong Chen; Lin-Tong Yu; Bai-Ru Cheng; Jiang-Lin Xu; Yun Cai; Jia-Lin Jin; Ru-Li Feng; Long Xie; Xin-Yan Qu; Dong Li; Jing Liu; Yan Li; Xiao-Yun Cui; Jin-Jin Lu; Kun Zhou; Qian Lin; Jie Wan
Journal:  Front Cardiovasc Med       Date:  2022-02-17

5.  Therapeutic Effect of Gypenosides on Antioxidant Stress Injury in Orbital Fibroblasts of Graves' Orbitopathy.

Authors:  Chao Ma; Haoyu Li; Wei Liu; Shuwen Lu; Xian Li; Jinyuan Chen; Kaijun Li; Wenzhan Wang
Journal:  J Immunol Res       Date:  2022-09-15       Impact factor: 4.493

6.  Activity Components from Gynostemma pentaphyllum for Preventing Hepatic Fibrosis and of Its Molecular Targets by Network Pharmacology Approach.

Authors:  Yumeng Zhang; Guohui Shi; Zhonghua Luo; Jiewen Wang; Shao Wu; Xiaoshu Zhang; Yuqing Zhao
Journal:  Molecules       Date:  2021-05-18       Impact factor: 4.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.